The HSI closed at 24,312, down 181 pts or 0.74%. Full-day turnover reached HKD270.412 billion. The HSTECH closed at 4,669, up 10 pts or 0.22%, while the HSCEI closed at 8,144, down 96 pts or 1.17%.

Major techs were mixed. KUAISHOU-W (01024.HK)’s Kling AI is reportedly seeking to raise over USD2 billion at a post-investment valuation of USD18 billion. Its shares bucked the market to close up 7.34% at HKD47.7. TENCENT (00700.HK) dipped 0.45%, BABA-W (09988.HK) faded 0.09%, and MEITUAN-W (03690.HK) dropped nearly 1.2%.

KINGBOARD HLDG (00148.HK) placed shares of KB LAMINATES (01888.HK) at an 11.5% discount. KB LAMINATES rattled in the morning, once diving 5.7%, before rebounding 6.87% to a record high of HKD91.8, and ended the day up 3.08%. KINGBOARD HLDG also opened lower but reversed course to finish up 17.68%.

Automakers posted notable declines. LI AUTO-W (02015.HK) shed 3.75%, the worst-performing blue chip of the day. XPENG-W (09868.HK) fell off 3.09%, while GEELY AUTO (00175.HK), BYD COMPANY (01211.HK) and NIO-SW (09866.HK) each slid more than 2%.

KNOWLEDGE ATLAS (02513.HK) officially launched and open-sourced GLM-5.2 today, with its shares skyrocketing 12.62%. MINIMAX-W (00100.HK) shot up 6.34%, while XUNCE (03317.HK) lost 2.56%.
~

AASTOCKS Financial News
Website: www.aastocks.com

Amazon.com, Inc. (AMZN.US)'s Amazon Web Services (AWS) held the AWS Summit Hong Kong and announced a deepening of its strategic partnership with Hong Kong Science and Technology Parks Corporation (HKSTPC).

The AWS Joint Innovation Center established by both parties will launch a new three-year strategic upgrade plan, promoting three major strategies: "Co-nurturing Startups", "Developing AI Talent" and "Empowering Global Expansion". The annual target of jointly supporting more than 100 startups will be stretched to cover the life and health technology sector.

Terry Wong, CEO of HKSTPC, said the upgrade of the AWS Joint Innovation Center will enable resources to be deployed more systematically into the most promising areas.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) were presented as an oral presentation at the 2026 European Hematology Association (EHA) Congress. Ligufalimab is Akeso's proprietary next-generation humanized IgG4 anti-CD47 monoclonal antibody. The study evaluated ligufalimab in combination with azacitidine (AZA) and venetoclax (VEN) in patients with treatment-naïve acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

Ligufalimab-based combination therapy demonstrates a significant trend toward survival benefit

• At a median follow-up of 10 months in the ligufalimab group and 8.8 months in the control group, median event-free survival (EFS) was 9.1 months in the ligufalimab group versus 6.9 months in the control group (hazard ratio [HR] = 0.46). The 6-month EFS rate was 67.8% versus 55.5% in the control group, and the 9-month EFS rate was 53.2% versus 14.1%.
• Median overall survival (mOS) was not reached in the ligufalimab group versus 8.3 months in the control group (HR = 0.46). The 6-month OS rate was 83.3% versus 73.2%, and the 9-month OS rate was 78.7% versus 43.1% in the control group.

Ligufalimab-based combination therapy yields deep tumor responses

• The objective response rate (ORR) was 80.0% in the ligufalimab group versus 66.7% in the control group, and the composite complete response (CRc) rate was 56.7% versus 53.3%; the proportion of patients achieving CRc with minimal residual disease (MRD) negativity was higher in the ligufalimab group than in the control group (46.7% vs. 36.7%).
• The median duration of CRc was 10.4 months in the ligufalimab group, which was markedly superior to 5.6 months in the control group.

Favorable Safety Profile With No New Safety Signals Observed

• The incidence of overall treatment-emergent adverse events (TEAEs) and serious adverse events was comparable between treatment arms. The most common TEAEs were generally consistent with those expected in the context of AML and AZA+VEN therapy.
• Anemia occurred in 46.7% of patients in the ligufalimab arm versus 50.0% in the control arm.

Notably, ligufalimab has already received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of AML. Akeso is advancing its ligufalimab clinical development programs at a globally competitive pace across both hematologic malignancies and solid tumors. Ligufalimab is also the first anti-CD47 monoclonal antibody worldwide to enter a registrational Phase III clinical trial in solid tumors.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, 27 candidates have advanced into clinical trials—including 15 bispecific or multispecific antibodies and bispecific ADCs—and 8 innovative drugs have reached commercial stage.

Through efficient and groundbreaking R&D, Akeso integrates premier global resources to develop transformative medicines, deliver high-quality, affordable therapeutic antibodies to patients worldwide, and generate sustained commercial and societal value as it strives to become a global leader in biopharmaceutical innovation.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

The HSI closed at 24,403 at midday, down 89 pts or 0.37%, with half-day turnover at HKD145.514 billion. The HSTECH closed at 4,666 at midday, up 8 pts or 0.18%, while the HSCEI closed at 8,179, down 60 pts or 0.73%.

Among major techs, General Atlantic is reportedly in talks to lead a financing of over USD2 billion for KUAISHOU-W (01024.HK)'s Kling AI. KUAISHOU-W rallied 5.81% at midday. TENCENT (00700.HK) gained over 1%. BABA-W (09988.HK) edged up 0.28%. MEITUAN-W (03690.HK) faded 0.33%.

Apple-related stocks bucked the market trend on reports that Apple Inc. (AAPL.US) plans to launch a series of new products by the end of next year, including camera-equipped AirPods and a second-generation foldable iPhone. SUNNY OPTICAL (02382.HK) leaped 8.45% at midday, making it the best-performing blue chip. ASMPT (00522.HK) swelled 3.91%, AAC TECH (02018.HK) added 2.76%, and LENS (06613.HK) hiked 1.8%.

KINGBOARD HLDG (00148.HK) placed shares in KB LAMINATES (01888.HK) at an 11.5% discount. KB LAMINATES fluctuated in the morning session, once diving 5.7% before rebounding to leap as much as 6.87%, and closed up 0.23% at midday. KINGBOARD HLDG also opened lower before rebounding, surging 16.87% at midday to HKD115.7.
~


AASTOCKS Financial News
Website: www.aastocks.com

Apple Inc. (AAPL.US) plans to launch a series of new products by the end of next year, including AirPods equipped with cameras, a second-generation foldable iPhone, and a new iPhone model to mark the 20th anniversary of the iPhone, Bloomberg, citing people with the knowledge of the matter, reported.

HK-listed Apple concept stocks bucked the market trend and ascended today (17th). SUNNY OPTICAL (02382.HK) last quoted at HKD80.65, up 8.11%. ASMPT (00522.HK) last quoted at HKD201.4, up 3.6%. AAC TECH (02018.HK) last quoted at HKD49, up 2.42%. LENS (06613.HK) last quoted at HKD28.2, up 1.37%.

The above products reportedly entered the later stages of development. The new AirPods will incorporate cameras into the earbud stems as computer vision sensors to provide Siri with information about the user’s surrounding environment and objects.

After launching its first foldable iPhone this year, Apple is expected to introduce a second-generation model by the end of next year, indicating that foldable devices may become part of Apple’s regular product upgrade cycle.
~

AASTOCKS Financial News
Website: www.aastocks.com

Digital infrastructure company Equinix, Inc. (EQIX.US) announced that its sixth International Business Exchange (IBX) data center in Hong Kong, HK6, has officially commenced operations.

HK6 is equipped with a liquid cooling system and is specifically designed to meet AI innovation demands for higher power density, enhanced heat dissipation efficiency, and operational resilience.

The initial investment in HK6 amounted to USD124 million (equivalent to approximately HKD1 billion). In its first phase, the facility provides a total of 1,000 cabinets. Upon full completion, HK6 will offer up to 3,550 cabinets.

HK6 directly connects to Equinix’s existing campus and the Hong Kong-Shenzhen Innovation and Technology Park (HSITP), linking tenants and start-ups in the Greater Bay Area. This not only helps promote cross-border collaboration but also accelerates research and development progress.

The AI Discovery Hub, jointly launched by Equinix, Hewlett Packard Enterprise Company (HPE.US) and NVIDIA Corporation (NVDA.US), has also been deployed at HK6, further advancing the implementation of AI innovation.
~

AASTOCKS Financial News
Website: www.aastocks.com

SpaceX (Space Exploration Technologies Corp. (SPCX.US)) extended upswing for a third consecutive trading day, soaring 4.83% overnight (16th) to close at USD201.8, with its market cap whopping USD2.65 trillion, surpassing Amazon.com, Inc. (AMZN.US) to become the world’s fifth-largest company by market value.

During overnight trading, SpaceX at one point hit an intraday peak of USD225.64, with its market cap briefly exceeding that of Microsoft Corporation (MSFT.US), making it the world’s fourth-largest listed company by market value for a short period.

Since its debut, SpaceX saw part of its share volatility from its relatively small public float, with only about 4.2% of shares available for trading on the first day of listing.

Market participants expect that as lock-up periods gradually expire, SpaceX’s share price may face greater downward pressure. The first batch of locked-up shares will become eligible for sale after the company releases its first earnings report.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, June 17, 2026 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company", Stock Code: 1833.HK) has recently upgraded its AI doctor service — Ping An AI Doctor. The service has been fully integrated into a number of core applications under Ping An Group, including Ping An Jin Guan Jia, Ping An Auto Owner, Ping An Pocket Bank and Ping An Le Health, reaching 90 million monthly active users.

Powered by the Ping An Medical Master® large model, the upgraded Ping An AI Doctor has established a service model centered on "AI responses in seconds + full-process supervision by human doctors". It is also deeply connected with the platform's unique "online, in-hospital, in-home, and in-company" healthcare service network. By integrating intelligent medical capabilities with a full-scenario ecosystem, Ping An AI Doctor is expected to promote the scalable, routine and inclusive implementation of premium family doctor services, providing the public with digital solutions for full-cycle health management.

Ping An AI Doctor breaks through the functional limitations of conventional intelligent Q&A tools. By deeply applying AI large models to clinical assistance scenarios, it can standardize professional services such as preliminary symptom screening, condition assessment, medication safety guidance, health risk assessment and personalized plan formulation. The platform supports 24/7 uninterrupted service and intelligent responses within seconds, responding to common daily health consultation needs in as fast as three seconds. This significantly shortens the time required for the public to access basic medical services and lowers the threshold for use.

To ensure medical quality and safety, the platform has established a full-process human doctor review mechanism. All diagnosis and treatment suggestions and health guidance plans generated by AI are reviewed and calibrated by licensed practicing physicians. For difficult conditions, complex chronic diseases or potential risks of serious conditions, the system will also automatically transfer the case to human doctors for follow-up, with specialists providing one-on-one in-depth consultations, thereby achieving "intelligent acceleration and efficiency enhancement, with professional medical support as a safeguard."

Leveraging Ping An Group's ecosystem advantages in multi-business collaboration, users do not need to download a separate application or mini-program. Instead, they can access relevant services with one click through high-frequency Ping An ecosystem portals, including insurance, banking and auto owner services. In terms of service system development, Ping An AI Doctor integrates Ping An's full-scenario medical resources across "online, in-hospital, in-home, and in-company" settings, forming a closed-loop health management service chain. It also offers functions such as health assessments, electronic medical records management, health checkup report interpretation and chronic disease management, covering healthy and sub-healthy populations as well as patients with common chronic diseases such as hypertension, diabetes and hyperlipidemia.

In medical service scenarios, Ping An AI Doctor connects users with more than 3,500 contracted experts from Grade A tertiary hospitals, over 5,100 partner hospitals and 240,000 branded chain pharmacies, providing one-stop services including precise triage, expert appointment booking, medical accompaniment and hospitalization assistance. Meanwhile, it supports emergency medication delivery in as fast as one hour, as well as in-home services such as home nursing, home-based health and elderly care, and postpartum recovery, further enhancing family health service scenarios.

Ping An Good Doctor will continue to deepen innovation in medical technology, iteratively enhance AI clinical assistance capabilities, and continuously expand high-quality offline medical resources and specialized health and elderly care services. The Company will further enrich full-scenario healthcare services, empower people's health through technology, safeguard family wellbeing with professional services, and continue contributing to the digital development of Healthy China.

CHANGSHA, China, June 16, 2026 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion") recently opened its second employee football league near the company's headquarters in Changsha, bringing together employees from across its subsidiaries and functions as global excitement for football continues to build.

Held under the theme "Youth in Motion, Football Dreams at Zoomlion," the league reflects Zoomlion's commitment to building an energetic workplace culture, encouraging cross-business collaboration and supporting employees' cultural and sports activities. The tournament features 13 teams from 19 business units, with more than 30 matches scheduled from May 29 to July 3.

The opening ceremony brought together representatives from Zoomlion's labor union, youth league committee and related subsidiaries and units. The 13 teams made their debut on the field, representing different subsidiaries and units across concrete machinery, agricultural machinery, aerial work platform, earthmoving machinery, mining machinery, emergency equipment, overseas operations, ZValley, Zoomlion Smart City and other corporate functions.

For Zoomlion, the league is more than a sports event. It is a platform designed to help employees from different teams to meet, compete and build trust beyond their daily roles. The same qualities seen on the football field, including focus, discipline, teamwork and the courage to challenge limits, also reflect Zoomlion's culture and the way its people work together across subsidiaries and functions.

Following the opening ceremony, a friendly match featuring company leaders and standout employee players brought the crowd together and set an energetic tone for the tournament.

"Football has always been a sport that brings people together," said Long Baijun, a player for the mining machinery team and director of Marketing Promotion Department at Zoomlion's mining machinery company. "On the field, we compete with focus, support each other and keep striving for victory. That same spirit is also part of our daily work at Zoomlion, where excellence, teamwork and resilience help us move forward together."

The league will continue over the coming weeks as teams compete through group matches and later rounds. By turning the football field into a shared space for competition, friendship and cross-functional connection, Zoomlion is further bringing its people-centered culture to life and encouraging employees to carry the same spirit of teamwork and perseverance from the pitch into their daily work.

SHANGHAI, June 16, 2026 /PRNewswire/ -- Shanghai Electric ("the Company") (SEHK: 02727, SSE: 601727) has successfully concluded its exhibition at the 2026 Shanghai International Carbon Neutrality Expo in Technologies, Products and Achievements (Carbon Neutrality Expo 2026) held from June 10 to 12 in Shanghai under the theme of "Engineering the Optimal Zero-Carbon Solution."

By presenting zero-carbon park construction achievements, low-carbon technology innovations and green product solutions, Shanghai Electric showcased its core capabilities in full-chain synergy, on-demand customization and project execution. Its integrated energy equipment value chain enables tailored solutions for diverse scenarios and supports green, low-carbon development.

Industrial parks are vital platforms for green and low-carbon development. At the expo, Shanghai Electric released the "White Paper on Technical Measures for Zero-Carbon Park Planning and Construction," offering systematic and actionable guidance for green and low-carbon park development. Centered on energy efficiency, energy substitution and resource circulation, Shanghai Electric offers end-to-end services from planning and construction to operations. Its full-chain solutions cover clean energy supply, low-carbon infrastructure, resource recycling and smart O&M.

In recent years, the Company has advanced several demonstration projects for green and low-carbon park development, including the "Zero-Carbon Bay" project in Shanghai's Lin-gang Special Area and a smart energy park in Shantou, Guangdong Province. Selected as one of China's first 52 national zero-carbon parks and the only project in Shanghai to receive the designation, the Lin-gang project highlights Shanghai Electric's role in planning, construction and operational deployment, as well as its ability to build integrated zero-carbon systems for advanced manufacturing industries. The Shantou project integrates wind, solar, storage, charging and intelligent energy management, and has received Guangdong's first carbon neutrality certificate.

With full-category new energy capabilities across wind, solar, storage, hydrogen and nuclear, Shanghai Electric covers the zero-carbon chain from generation to smart platforms and energy-saving equipment. The full-chain synergy provides robust technological and industrial foundation for building zero-carbon scenarios.

Shanghai Electric also released social carbon reduction contribution data for the second consecutive year. In 2025, the Company achieved a reduction of approximately 389 million tons of CO₂ equivalent, continuing to apply its green technologies and industrial capabilities to drive low-carbon transition.

Meanwhile, Shanghai Electric unveiled its next-phase ESG development strategy, reaffirming its commitment to clean technology innovation, low-carbon management and sustainability governance as it works with global partners to support the global zero-carbon transition.